度洛西汀联合巴戟天寡糖胶囊治疗卒中后抑郁的临床研究

发布时间：2018-10-26 11:42

【摘要】：目的:探讨度洛西汀联合巴戟天寡糖胶囊治疗卒中后抑郁的临床疗效。方法:108例患者按随机数字表分为三组,除接受常规药物治疗外,分别口服度洛西汀和巴戟天寡糖胶囊、联合度洛西汀和巴戟天寡糖胶囊,于治疗前和治疗后4、8周,采用汉密尔顿抑郁量表(HAMD)、美国国立卫生研究院卒中量表(NIHSS)、Barthei指数(BI)、简易智能状态量表(MMSE)和副反应量表(TESS)评定患者的临床疗效、神经功能、认知功能和副反应状况。结果:治疗8周后,度洛西汀组和巴戟天组有效率差异无统计学意义(P0.05),联合组与度洛西汀组、巴戟天组有效率差异均有统计学意义(P0.05),三组不良反应发生率差异无统计学意义(P0.05);联合组和度洛西汀组HAMD评分较治疗前均极显著下降(P0.01),巴戟天组显著下降(P0.05);三组NIHSS评分均较治疗前极显著下降(P0.01),BI评分、MMSE评分均较治疗前显著升高(P0.01);联合组与度洛西汀组、巴戟天组比较,HAMD评分极显著下降(P0.01);NIHSS评分、BI评分差异均无统计学意义(P0.05);MMSE评分则显著升高(P0.05)。结论:度洛西汀与巴戟天寡糖胶囊对卒中后抑郁均有较好的疗效和安全性,联合用药疗效和改善认知功能更好。
[Abstract]:Objective: to investigate the clinical effect of doxicetine combined with Morinda officinalis oligosaccharide capsule on post-stroke depression. Methods: one hundred and eight patients were randomly divided into three groups. In addition to routine drug therapy, they were treated by oral administration of doloxetine and Morinda officinalis oligosaccharide capsules, combined with doloxetine and Morinda officinalis oligosaccharide capsules. The Hamilton Depression scale (HAMD), the (NIHSS), Barthei Index of Stroke scale (NIHSS), Barthei), the (BI), Mini-Mental State scale (MMSE) and the side effects scale (TESS) were used to evaluate the clinical efficacy and neurological function of the patients. Cognitive function and side effects. Results: after 8 weeks of treatment, there was no significant difference in the effective rate between Doxetine group and Morinda officinalis group (P0.05), but there was significant difference in the effective rate between the combined group, the doxicetine group and the Morinda officinalis group (P0.05). There was no significant difference in the incidence of adverse reactions among the three groups (P0.05). The HAMD scores in combination group and doxetine group were significantly lower than those before treatment (P0.01), and Morinda officinalis group significantly decreased (P0.05). The NIHSS scores in the three groups were significantly lower than those before treatment (P0.01), BI score, MMSE score were significantly higher than those before treatment (P0.01), and the HAMD scores in the combined group, Doxetine group and Morinda officinalis group were significantly decreased (P0.01). There was no significant difference in NIHSS score and BI score (P0.05); MMSE score was significantly higher (P0.05). Conclusion: both doxoxetine and Morinda officinalis oligosaccharide capsules have better efficacy and safety in the treatment of post-stroke depression.
【作者单位】：皖南医学院弋矶山医院医学心理科;芜湖市第四人民医院;皖南医学院弋矶山医院神经内科;
【分类号】：R743.3;R749.4

【相似文献】